Q1 Earnings Estimate for Genmab A/S Issued By William Blair

Genmab A/S (NASDAQ:GMAB) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps anticipates that the company will post earnings of $0.37 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S’s Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.62 EPS and Q4 2026 earnings at $0.67 EPS.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

GMAB has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Truist Financial cut their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Stock Performance

Genmab A/S stock opened at $19.84 on Wednesday. The firm has a market cap of $13.13 billion, a P/E ratio of 11.40, a P/E/G ratio of 2.65 and a beta of 0.98. The business’s fifty day moving average is $21.09 and its two-hundred day moving average is $22.25. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.02.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GMAB. Natixis Advisors LLC increased its holdings in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after purchasing an additional 47,437 shares during the last quarter. Grandfield & Dodd LLC increased its holdings in shares of Genmab A/S by 25.7% in the third quarter. Grandfield & Dodd LLC now owns 32,363 shares of the company’s stock worth $789,000 after acquiring an additional 6,610 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after acquiring an additional 12,654 shares in the last quarter. Eagle Asset Management Inc. increased its holdings in shares of Genmab A/S by 10.0% in the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after acquiring an additional 1,121 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Genmab A/S by 14.6% in the third quarter. Cerity Partners LLC now owns 48,003 shares of the company’s stock worth $1,170,000 after acquiring an additional 6,103 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.